Viking completes enrollment in Phase II hip fracture trial of VK5211

Viking Therapeutics Inc. (NASDAQ:VKTX) completed enrollment of 108 patients ages ≥65 recovering from hip fracture surgery in a Phase II trial of VK5211. Top-line data are expected in 4Q17.

The double-blind, placebo-controlled, international study is evaluating 0.5, 1 and 2 mg doses of oral VK5211 once daily for 12 weeks. The primary endpoint is change from baseline in lean body mass after week 12. Secondary endpoints include functional performance, quality of life (QOL), activities of daily living, safety and pharmacokinetics...